B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

HOXA9

MOLECULAR TARGET

homeobox A9

NCBI Gene: 320511 compounds

HOXA9 (homeobox A9) is targeted by 11 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting HOXA9

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Adenosine0.691
2Ampicillin Semi-synthetic derivative of penicillin that functions as0.691
3Equilin0.691
4Ethidium0.691
5felbinac0.691
6Fusaric Acid0.691
7gamma-Linolenic Acid0.691
8Harmaline0.691
9p-Aminohippuric Acid0.691
10Temozolomide0.691
11Trifluridine0.691

About HOXA9 as a Drug Target

HOXA9 (homeobox A9) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 11 compounds with documented HOXA9 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

HOXA9 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.